Clinical TrialsThe Phase 2 TROPOS study for cibotercept was terminated early due to unanticipated pericardial effusion events and a risk/benefit assessment.
Market CatalystsWithout the PAH program, which was a major focus for investors, there are limited near-term catalysts from the partnered elritercept program.
ValuationKeros Therapeutics, Inc. is being downgraded from OUTPERFORM to NEUTRAL after removing cibotercept for PAH and KER-065 for obesity from their valuation.